GlassScriptPhysician profile
Tonya C Cockrill
NPI 1811122641
$83,347.32
in general payments reported to CMS, 2019-2025
22 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $7,218 · 2021: $7,226 · 2022: $12K · 2023: $25K · 2024: $3,626 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $6,711 · Travel and Lodging: $2,948 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,900.00 |
| Food and Beverage | $6,710.70 |
| Travel and Lodging | $2,948.20 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75,047.47 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $2,560.46 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $1,040.59 | 2019-2025 | |
| Pfizer INC. | $909.45 | 2019-2025 | |
| Lilly USA, LLC | $695.81 | 2019-2024 | Taltz |
| Ucb, INC. | $667.86 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $591.02 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $534.35 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $305.65 | 2019-2025 | Orencia |
| Radius Health, INC. | $204.79 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $139.56 | 2019-2025 | Actemra, Gazyva |
| Organon LLC | $133.43 | 2022-2025 | Renflexis, Hadlima |
| Celgene Corporation | $127.72 | 2019 | |
| Genzyme Corporation | $108.71 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $67.09 | 2023-2024 | Lupkynis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $42.96 | 2019 | |
| Horizon Therapeutics Plc | $42.77 | 2021-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $30.04 | 2019-2025 | Benlysta |
| Invivyd INC | $29.54 | 2025 | Pemgarda |
| Octapharma USA, INC. | $26.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.10 | 2022 | |
| Hikma Pharmaceuticals USA | $16.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Cockrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.